BEAT today
$0.37-$0.03 (-7.90%)close Nov 13, 2026Trend
DailyUptrend (starting)
4 hourSymmetric Triangle
1 hourExpanding
15 minSymmetric Triangle
5 minStrong Bearish
Daily trend turns down below $0.35
Key levels
Resistance$0.52
Resistance$0.42
Support$0.35
Latest news & SEC filings
EarningsHeartBeam posts Q3 2026 results covering finances and operations
EarningsHeartBeam posts smaller quarterly loss than expected
All BEAT news →About HeartBeam
HeartBeam is a medical technology company that makes portable heart-monitoring devices. Its main offering, the HeartBeam System, is a credit card-sized recorder that gathers the heart's activity from three directions and produces a standard twelve-lead readout to help assess irregular heart rhythms. The system also includes a patient app, a doctor portal, and cloud software, with results interpreted by cardiologists. The company sells to specialty heart clinics, hospitals, and research studies, initially in the United States.
Based on the company's 10-K filed Mar 12, 2026.
Nasdaq · Healthcare
HeartBeam, Inc. (BEAT)
What Is the Price Target for BEAT?
SEPT Low Target
$2.00
SEPT Mid Target
$2.50
SEPT High Target
$4.00
Analyst Consensus
$2.50
Is BEAT a Buy or Sell Right Now?
Thesis
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for BEAT.
Start Free Trial →Is BEAT Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$1.98
4
Moat Score
NONE
2/9
Piotroski Score
-27.6
Altman Z-Score
What Is Smart Money Doing with BEAT?
Insider Signal
BUYING
9 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →BEAT Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
15.07%
FCF Growth YoY
0.6%
Revenue Trend
UNKNOWN
Dark Pool Trades for BEAT
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for BEAT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:04:33 | $0.37 | 1,000 | $$372 | SELL |
| 17:57:47 | $0.37 | 1,000 | $$372 | BUY |
| 17:44:10 | $0.37 | 1,916 | $$709 | BUY |
| 17:43:33 | $0.37 | 1,000 | $$370 | BUY |
| 17:41:48 | $0.37 | 1,000 | $$370 | SELL |
5 dark pool trades shown · $$2K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for HeartBeam, Inc. (BEAT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →BEAT — frequently asked questions
What is BEAT stock price today?
HeartBeam, Inc. (BEAT) is at $0.37, down 7.90% (-$0.03) at the Nov 13, 2026 close.
Why is BEAT stock moving today?
Latest BEAT news — Nov 13, 2026: HeartBeam posts Q3 2026 results covering finances and operations · Nov 12, 2026: HeartBeam posts smaller quarterly loss than expected
Why did BEAT stock move on Nov 2, 2026?
HeartBeam (BEAT) announced positive pilot study results for its heart attack detection technology at TCT 2026, with the device achieving 81.8% specificity versus 71.4% for a standard ECG. The company also disclosed plans for a U.S.
What is the BEAT price target?
The average analyst price target for BEAT is $2.50, ranging from $2 to $4, based on 3 analysts. Latest: Maxim Group initiates on Jul 14, 2026.
What do analysts rate BEAT?
Analyst ratings for BEAT: 3 Buy, 3 Hold, 0 Sell — consensus Hold.
Did BEAT beat earnings?
BEAT last reported on Aug 13, 2026: EPS -$0.10 vs -$0.09 expected — a miss of 16.3%.
Does BEAT pay a dividend?
BEAT does not currently pay a dividend.
What are BEAT support and resistance levels?
Support: $0.35. Resistance: $0.42, $0.52, $0.57.
What are insiders doing with BEAT?
Insider activity: BUYING, 9 buys and 0 sells in the last 90 days.
What is the latest news on BEAT?
Nov 13, 2026: HeartBeam posts Q3 2026 results covering finances and operations · Nov 12, 2026: HeartBeam posts smaller quarterly loss than expected